ReviewClinical, cosmetic and investigational dermatology2020
Diagnosis, Screening and Treatment of Patients with Palmoplantar Pustulosis (PPP): A Review of Current Practices and Recommendations.
Review in Clinical, cosmetic and investigational dermatology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 49 citations in OpenAlex.
- Risankizumab in Japanese patients with moderate-to-severe palmoplantar pustulosis: Results from the randomized, phase 3 JumPPP study.The Journal of dermatology · 2025Trial
- Efficacy and Safety of Brodalumab, an Anti-interleukin-17 Receptor A Monoclonal Antibody, for Palmoplantar Pustulosis: 16-Week Results of a Randomized Clinical Trial.American journal of clinical dermatology · 2024Trial
- Efficacy and Safety of Apremilast for the Treatment of Japanese Patients with Palmoplantar Pustulosis: Results from a Phase 2, Randomized, Placebo-Controlled Study.American journal of clinical dermatology · 2023Trial
- Sustained efficacy and safety of guselkumab in patients with palmoplantar pustulosis through 1.5 years in a randomized phase 3 study.The Journal of dermatology · 2021Trial
- Efficacy of upadacitinib in palmoplantar pustulosis case series highlights the complex immune response patterns.Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG · 2026Article
- Janus Kinase Inhibitors for Treatment of Palmoplantar Pustulosis, Generalized Pustular Psoriasis, and Palmoplantar Pustular Psoriasis: A Systematic Review of the Literature.Health science reports · 2026Review
- Evaluation of Diabetes Mellitus, Hyperlipidemia, and Thyroid Disease Comorbidities in Palmoplantar Pustulosis.The Eurasian journal of medicine · 2026Article
- Clinical and immunomicrobiome correlates of a standardized Qingpao Chushi Jiedu Fang regimen in palmoplantar pustulosis.Frontiers in medicine · 2026Article
- Targeting the JAK/STAT pathway in palmoplantar pustulosis: a review.Annals of medicine · 2025Review
- Topical Crisaborole for the Treatment of Recalcitrant Palmoplantar Pustulosis: A Case Series.Dermatology and therapy · 2025Article
- Successful treatment of refractory palmoplantar pustulosis using JAK-1 inhibitors and TYK-2 inhibitors: a real-world retrospective study.Postepy dermatologii i alergologii · 2025Article
- Disease features, treatments, and burden of palmoplantar pustulosis in Korea: The EPPPIK study.The Journal of dermatology · 2025Article
- Epidemiology of generalized pustular psoriasis in Germany: Analyzing factors influencing prevalence estimates health insurance data.Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG · 2025Article
- Considerations for defining and diagnosing generalized pustular psoriasis.Journal of the European Academy of Dermatology and Venereology : JEADV · 2025Review
- Case Report: Successful management of refractory palmoplantar pustulosis with upadacitinib.Frontiers in immunology · 2025Article
- JAK inhibitors for the treatment of palmoplantar pustulosis: a narrative review.Drugs in context · 2025Review
- Assessment of sexual function in patients with palmoplantar pustulosis: a cross-sectional study.Archives of dermatological research · 2024Article
- Paradoxical Psoriasis in Patients Receiving Therapy with Tumor Necrosis Factor Inhibitors: Potential Pathogenic Mechanisms and the Role of Genetic Factors.International journal of molecular sciences · 2024Review
- Response to: Letter to Editor Regarding "Spesolimab Efficacy and Safety in Patients with Moderate-to-Severe Palmoplantar Pustulosis: A Multicentre, Double-Blind, Randomised, Placebo-Controlled, Phase IIb, Dose-Finding Study".Dermatology and therapy · 2024Article
- Treatment Patterns and Negative Health Outcomes in Palmoplantar Pustulosis Patients in Germany and the US.Dermatology and therapy · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Palmoplantar pustulosis (PPP) is a rare, chronic, recurrent inflammatory disease that affects the palms and/or the soles with sterile, erupting pustules, which are debilitating and usually resistant to treatment. It has genetic, histopathologic and clinical features that are not present in psoriasis; thus, it can be classified as a variant of psoriasis or as a separate entity. Smoking and upper respiratory infections have been suggested as main triggers of PPP. PPP is a challenging disease to manage, and the treatment approach involves both topical and systemic therapies, as well as phototherapy and targeted molecules. No gold standard therapy has yet been identified, and none of the treatments are curative. In patients with mild disease, control may be achieved with on-demand occlusion of topical agents. In patients with moderate-to-severe PPP, phototherapy or a classical systemic agent (acitretin being the best treatment option, especially in combination with PUVA) may be effective. Refractory patients or those with contraindications to use these therapies may be good candidates for apremilast or biologic therapy, particularly anti-IL-17A and anti-IL-23 agents. Recent PPP trials are focusing on blockage of IL-36 or IL-1 pathways, which play an important role in innate immunity. Indeed, IL-36 isoforms have been strongly implicated in the pathogenesis of psoriasis. Therefore, blockage of the IL-36 pathway has become a new treatment target in PPP, and three studies are currently evaluating the use of monoclonal antibodies that block the IL-36 receptor in PPP: ANB019 and spesolimab (BI 655130). In this review, we explore the diagnosis, screening and treatment of patients with PPP.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.